First Frontline Clinical Trial to Treatment Pediatric Hodgkin Lymphoma with Targeted Therapy Shows Excellent...

A new study showed that the addition of the anti-CD30 antibody drug brentuximab vedotin effectively reduces side effects and radiation exposures for in high-risk pediatric Hodgkin lymphoma. The study was published in the Journal...
Advertisement

Journal Reading List

Multiple Myeloma Knowledge Hub

FDA Extends Approval of Immunotherapy Agent Keytruda® to Include Esophageal Cancer

Melflufen Combination Approved for Heavily Pretreated Multiple Myeloma

On March 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (melflufen) in combination with dexamethasone for the treatment...

KarMMA: BCMA CAR-T Spurs Lasting Remission in Relapsed/Refractory MM

The latest updates from the KarMMA trial, published in The New England Journal of Medicine, showed that treatment with idecabtagene vicleucel (ide-cel) for relapsed/refractory...
video

Dr. Hari Discusses Upfront Autologous Transplantation for Multiple Myeloma

Parameswaran Hari, MD, Chief of Hematology/Oncology at the Medical College of Wisconsin, spoke with DocWire News about how new therapeutic agents are changing the...

Double ASCT in MM Does Not Increase Survival Compared to Single ASCT

Patients with multiple myeloma (MM) who underwent double autologous stem cell transplantation (ASCT) did not have better overall survival (OS) and progression-free survival (PFS)...
IV bag

POLLUX and CASTOR: Daratumumab Combinations for MM Prolong MRD-Negativity

Therapeutic regimens for multiple myeloma (MM) that use a combination of the anti-CD38 monoclonal antibody daratumumab induce higher rates of sustained minimal residual disease...
Benzodiazepine Use On The Rise to Treat Pain

Real-World Efficacy of All-Oral Triplet Regimen for Myeloma

In an analysis of real-world data, the all-oral triplet regimen of ixazomib, lenalidomide, and dexamethasone (IRD) for the treatment of multiple myeloma (MM) was...
Prognostic Value of Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity

Low One-Year Adherence to Lenalidomide in Multiple Myeloma

Real-world data from a single institution showed concerningly low levels of long-term adherence to lenalidomide therapy for multiple myeloma (MM). For this study, researchers sought...
video

Benefits of Antibody Drug Conjugates for Multiple Myeloma, with Dr. Chakraborty

DocWire News spoke with Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, Division of Hematology/Oncology, on the benefits of...
Advertisement
Advertisement